EW - Edwards Lifesciences topline up 2% misses Q4 profit consensus

Edwards Lifesciences (EW) Q4 results:Net sales: $1.19B (+1.7%), Transcatheter Aortic Valve Replacement: $776.2M (+1.8%); Surgical Structural Heart: $204.2M(-0.5%); Critical Care: $198.2M (-0.6%).Net income: $309.5M (+10.5%); EPS: $0.49 (+11%); non-GAAP EPS: $0.50 (+2%).2021 guidance: Non-GAAP EPS: $2.00 to $2.20.Cash and investments totaled $2.2B at December 31, 2020.  Total debt was $595M.Previously (Jan. 27): Edwards Lifesciences EPS misses by $0.03, beats on revenue

For further details see:

Edwards Lifesciences topline up 2%, misses Q4 profit consensus